Isoguavacine, an old experimental compound which exclusively targets peripheral neurons, mitigates abnormal touch sensitivity in mouse models of ASD. The compound also improved body mass, reduces anxiety, and in one genetic subset of mice, prevented the development of brain abnormalities that arise from altered touch response.
